CNS Pharmaceuticals (NASDAQ:CNSP) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
by Danessa Lincoln · The Markets DailyCNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.03, FiscalAI reports.
CNS Pharmaceuticals Stock Up 20.4%
NASDAQ:CNSP opened at $3.48 on Tuesday. The stock’s 50-day simple moving average is $4.91 and its 200 day simple moving average is $4.46. CNS Pharmaceuticals has a twelve month low of $1.90 and a twelve month high of $10.54.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Read Our Latest Research Report on CNS Pharmaceuticals
About CNS Pharmaceuticals
CNS Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancers of the brain and central nervous system. Its research has centered on investigational therapies intended to address the challenges of treating tumors that affect these areas. The company’s lead candidate has been berubicin, an experimental anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated berubicin for glioblastoma, an aggressive form of brain cancer. The drug remains investigational and is not an approved treatment.
Read More
- Five stocks we like better than CNS Pharmaceuticals
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness